Trigeminal Nerve Stimulation for Anxiety Disorders
Trial Summary
Will I have to stop taking my current medications?
Yes, you will need to stop taking medications for anxiety disorders, antidepressants, and benzodiazepines to participate in this trial.
What data supports the effectiveness of the treatment Trigeminal Nerve Stimulation for anxiety disorders?
Is trigeminal nerve stimulation (TNS) safe for humans?
How does trigeminal nerve stimulation treatment differ from other treatments for anxiety disorders?
Trigeminal nerve stimulation (TNS) is unique because it is a non-invasive treatment that uses external electrodes to stimulate the trigeminal nerve, which may influence brain areas involved in mood and anxiety regulation. Unlike traditional medications, TNS does not involve taking drugs and has shown promise in improving mood and anxiety in conditions like epilepsy and depression.12357
What is the purpose of this trial?
This trial is testing a treatment called trigeminal nerve stimulation, which involves sending electrical signals to a nerve in the face. It aims to help patients with panic disorder, generalized anxiety disorder, and social anxiety disorder. The treatment works by calming brain activity to reduce anxiety symptoms. Trigeminal nerve stimulation (TNS) is a promising strategy in treating diseases of the nervous system, including epilepsy and traumatic brain injury.
Research Team
Rafael Freire, MD PhD
Principal Investigator
Department of Psychiatry, Queen's University
Eligibility Criteria
This trial is for individuals who have been diagnosed with panic disorder, social anxiety disorder, or generalized anxiety disorder according to DSM5 criteria. It's not specified who can't join the trial.Inclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive trigeminal nerve stimulation or sham stimulation at home for 8 hours per night, 7 days a week for 8 weeks
Follow-up
Participants are monitored for sustained response and remission two weeks after the end of treatment
Treatment Details
Interventions
- Trigeminal Nerve Stimulation
Trigeminal Nerve Stimulation is already approved in United States, European Union for the following indications:
- Attention Deficit Hyperactivity Disorder (ADHD) in children aged 7-12
- Migraine prevention and treatment
Find a Clinic Near You
Who Is Running the Clinical Trial?
Dr. Rafael Freire
Lead Sponsor
Dr. Rafael Freire
Lead Sponsor